dc.creator | Maza Solano, Juan Manuel | es |
dc.creator | Calvo-Henríquez, Christian | es |
dc.creator | Alobid, Isam | es |
dc.creator | Álvarez-Cendrero, Marta | es |
dc.creator | Palomares, Óscar | es |
dc.creator | Moreno-Luna, Ramón | es |
dc.creator | Santos-Perez, Jaime | es |
dc.creator | Sánchez Gómez, Serafín | es |
dc.date.accessioned | 2023-10-11T12:55:34Z | |
dc.date.available | 2023-10-11T12:55:34Z | |
dc.date.issued | 2022-11-29 | |
dc.identifier.citation | Maza Solano, J.M., Calvo-Henríquez, C., Alobid, I., Álvarez-Cendrero, M., Palomares, Ó., Moreno-Luna, R.,...,Sánchez Gómez, S. (2022). Nasal symptoms in asthmatic patients under treatment with anti-IL-5 monoclonal antibodies. A real-life cohort study. JOURNAL OF CLINICAL MEDICINE, 11 (33). https://doi.org/10.3390/jcm11237056. | |
dc.identifier.issn | 2077-0383 | es |
dc.identifier.uri | https://hdl.handle.net/11441/149651 | |
dc.description.abstract | Currently, some monoclonal antibodies (mAbs) are being studied for chronic rhinosinusitis
with nasal polyps (CRSwNP). Three anti-IL-5 mAb: mepolizumab, reslizumab and benralizumab,
have been tested through randomized clinical trials. In this real-life study, we aimed to describe the
nasal effects of a cohort of asthmatic adults treated with anti-IL-5 mAb. Methods: We carried out
an observational study in adults (≥18 years) on anti-IL-5 mAb treatment. Variables included ACT
and SNOT−22 questionnaires, nasal polyps score, blood total IgE levels and blood eosinophil count.
Results: Overall, 38 participants were included in the study; 19 patients received mepolizumab, 17
were treated with benralizumab and 2 patients were given reslizumab. There was a statistically
significant difference in the ACT and SNOT−22 scores before and after mAb treatment. ACT score
increased from 11.05 to 21.5 after treatment (p < 0.001). SNOT−22 decreased from 57 to 37.3 after
treatment (p = 0.004). No statistically significant differences between mAb groups were observed
regarding the ACT or the SNOT−22 (p = 0.775) response (p = 0.775). In addition, 60.53% of patients
obtained a minimal clinically important difference (MCID) in SNOT−22. Conclusions: A significant
clinical response based on SNOT−22 score evolution after anti-IL-5 mAb treatment was observed.
This study also demonstrated that blood eosinophil count, rather than serum total IgE levels, is
the best predictor of asthma symptom improvement, which was assessed through the ACT and
SNOT−22 questionnaires. | es |
dc.format | application/pdf | es |
dc.format.extent | 11 p. | es |
dc.language.iso | eng | es |
dc.publisher | MDPI | es |
dc.relation.ispartof | JOURNAL OF CLINICAL MEDICINE, 11 (33). | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Asthma | es |
dc.subject | Benralizumab | es |
dc.subject | Chronic rhinosinusitis | es |
dc.subject | Mepolizumab | es |
dc.subject | Nasal polyps | es |
dc.subject | Reslizumab | es |
dc.title | Nasal symptoms in asthmatic patients under treatment with anti-IL-5 monoclonal antibodies. A real-life cohort study | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Cirugía | es |
dc.relation.publisherversion | https://www.mdpi.com/2077-0383/11/23/7056 | es |
dc.identifier.doi | 10.3390/jcm11237056 | es |
dc.journaltitle | JOURNAL OF CLINICAL MEDICINE | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 33 | es |